CL2015003333A1 - Vacunas de e1e2 del vhc y métodos de uso - Google Patents

Vacunas de e1e2 del vhc y métodos de uso

Info

Publication number
CL2015003333A1
CL2015003333A1 CL2015003333A CL2015003333A CL2015003333A1 CL 2015003333 A1 CL2015003333 A1 CL 2015003333A1 CL 2015003333 A CL2015003333 A CL 2015003333A CL 2015003333 A CL2015003333 A CL 2015003333A CL 2015003333 A1 CL2015003333 A1 CL 2015003333A1
Authority
CL
Chile
Prior art keywords
vhc
vaccines
methods
Prior art date
Application number
CL2015003333A
Other languages
English (en)
Spanish (es)
Inventor
Michael Houghton
Darren Hockman
John L Law
Michael Logan
Lorne D Tyrrell
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of CL2015003333A1 publication Critical patent/CL2015003333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015003333A 2013-05-15 2015-11-13 Vacunas de e1e2 del vhc y métodos de uso CL2015003333A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US201361887229P 2013-10-04 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Publications (1)

Publication Number Publication Date
CL2015003333A1 true CL2015003333A1 (es) 2016-09-30

Family

ID=54054625

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003333A CL2015003333A1 (es) 2013-05-15 2015-11-13 Vacunas de e1e2 del vhc y métodos de uso

Country Status (8)

Country Link
US (3) US20210145963A9 (enExample)
EP (2) EP2996718B1 (enExample)
JP (5) JP2016520077A (enExample)
CN (2) CN112999344A (enExample)
AU (3) AU2014385320B2 (enExample)
CA (1) CA2909586C (enExample)
CL (1) CL2015003333A1 (enExample)
WO (1) WO2015132619A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491735A3 (en) * 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
CN109963587A (zh) * 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
AU2017341735B2 (en) 2016-10-11 2022-01-13 Helmholtz Center for Infection Research Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
EP3765075A4 (en) 2018-03-16 2021-12-08 The Governors of the University of Alberta HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF
WO2025222304A1 (en) * 2024-04-26 2025-10-30 The Governors Of The University Of Alberta Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998050556A2 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
CA2909586A1 (en) 2015-09-11
US20210145963A9 (en) 2021-05-20
JP2016520077A (ja) 2016-07-11
HK1216395A1 (en) 2016-11-11
US20240316186A1 (en) 2024-09-26
EP3689375A1 (en) 2020-08-05
US20230098265A1 (en) 2023-03-30
AU2014385320B2 (en) 2019-10-10
CN105263517A (zh) 2016-01-20
EP2996718A4 (en) 2017-06-21
AU2020200216A1 (en) 2020-02-06
CN112999344A (zh) 2021-06-22
EP2996718A1 (en) 2016-03-23
CN105263517B (zh) 2021-03-26
AU2014385320A1 (en) 2015-11-12
CA2909586C (en) 2021-08-31
EP2996718B1 (en) 2020-01-15
JP2024156917A (ja) 2024-11-06
JP2022172244A (ja) 2022-11-15
WO2015132619A1 (en) 2015-09-11
US20160067332A1 (en) 2016-03-10
JP2019142962A (ja) 2019-08-29
AU2022200747A1 (en) 2022-02-24
JP2021059596A (ja) 2021-04-15

Similar Documents

Publication Publication Date Title
HUS2200041I1 (hu) Anti-CD3 antitestek és alkalmazási eljárások
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
IL251970B (en) Anti-cd79b antibodies and methods of use
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
HUE051982T2 (hu) Anti-alfa-szinuklein antitestek és alkalmazási eljárások
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
HUE059701T2 (hu) Antitestek és felhasználási módszerek
SI3258951T1 (sl) Anti-pvrig protitelesa in metode uporabe
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
PL3623943T3 (pl) Urządzenie przenośne i sposób ograniczania korzystania z urządzenia przenośnego
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
HUE053033T2 (hu) Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
CL2016000235A1 (es) Inhibidores de rorc2 y sus métodos de uso
IL244590A0 (en) Anti-epcam antibodies and methods of use
CR20180296A (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
CO6940375A2 (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
EP2989432C0 (en) IMAGING APPARATUS AND METHOD
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
BR112016004943A2 (pt) aparelho médico e uso
IL244354B (en) Influenza vaccine and therapy